Evoke Wealth LLC Acquires 228 Shares of Cencora, Inc. (NYSE:COR)

Evoke Wealth LLC boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,075 shares of the company’s stock after buying an additional 228 shares during the period. Evoke Wealth LLC’s holdings in Cencora were worth $466,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares during the period. SBI Securities Co. Ltd. bought a new stake in Cencora during the fourth quarter valued at $30,000. Kentucky Trust Co bought a new stake in Cencora during the fourth quarter worth about $33,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,648 shares of company stock worth $3,382,462 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Cencora Stock Up 1.2 %

Shares of NYSE:COR opened at $264.02 on Wednesday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $281.45. The company has a market cap of $51.20 billion, a PE ratio of 37.56, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock’s 50-day moving average is $248.84 and its 200 day moving average is $239.49.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.83%. Cencora’s dividend payout ratio is presently 31.29%.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company lifted their price target on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Finally, Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.